---
title: "Lilly reports positive results for Omvoh in Crohn's disease"
date: "2025-02-07 17:58:59"
summary: "Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the majority of patients receiving the drug continuously for two years achieved long-term clinical and endoscopic outcomes, including 43.8% with..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Eli Lilly (NYSE:[LLY](https://seekingalpha.com/symbol/LLY "Eli Lilly and Company")) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease.

The study, called VIVID-2, showed that the majority of patients receiving the drug continuously for two years achieved long-term clinical and endoscopic outcomes, including 43.8% with previous biologic failure, [according to a statement](https://seekingalpha.com/pr/19995383-most-patients-on-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-achieved-sustained-clinical).

Data from the study is slated to presented at the Crohn's and Colitis Congress, which is being held Feb. 6-8 in San Francisco.

Omvoh received FDA approval for Crohn's in January. The drug is also approved for ulcerative colitis.

The European Medicines Agency issued a positive opinion in December for the approval of Omvoh for moderately to severely active Crohn's disease.

[seekalpha](https://seekingalpha.com/news/4405158-lilly-reports-positive-results-for-omvoh-in-crohns-disease)
